Charles M. Quick

High Impact

Professor

UAMS

Last publication 2026 Last refreshed 2026-05-16

faculty

Pathology, College of Medicine

35 h-index 204 pubs 3,913 cited

Research Areas

Links

Lab Website Research Group UAMS TRI Profile

OverviewAI-generated summary

Charles M. Quick is a Professor in Pathology at the University of Arkansas for Medical Sciences, College of Medicine. His research focuses on the integrated mutational landscape analysis of various gynecologic cancers, including uterine leiomyosarcomas and poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix. He has also investigated the potential for endometriosis progression in reproductive-age women, particularly concerning the co-existence of diabetes and endometriosis.

Dr. Quick's work extends to studying the immune response in cancer patients, including the expansion of Human Papillomavirus-specific T cells in therapeutic vaccine recipients and the longitudinal monitoring of tumor response to immune checkpoint inhibitors using noninvasive diffuse reflectance spectroscopy. His publications also address rare gynecologic tumors, such as gynandroblastoma of the ovary with DICER1 mutations and ovarian steroid cell tumors.

With a career marked by significant scholarly output, Dr. Quick has authored over 200 publications, amassing more than 3,800 citations and an h-index of 35. He is recognized as a highly cited researcher and actively leads a research group, collaborating with colleagues such as Michael Cho and Yong-Chen Lu at the University of Arkansas for Medical Sciences, and Narasimhan Rajaram at the University of Arkansas at Fayetteville.

Metrics

h-index: 35
Publications: 204
Citations: 3,913

Selected Publications

“Dark Paget” Cells in Extramammary Paget Disease of the Vulva—Diagnostic Features and Interpretative Pitfalls (2026)

DOI OpenAlex
Isolation of mitochondrial mutation-specific T cell receptors (2025)

3 citations DOI OpenAlex
A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i> (2025)

2 citations DOI OpenAlex
Interpretation of p16 and p53 in the Classification of Squamous Cell Carcinoma of the Vulva—An Interobserver Agreement Study (2024)

4 citations DOI OpenAlex
Human quad liver-on-chip system as a tool toward bridging the gap between animals and humans regarding toxicology and pharmacology of a cannabidiol-rich cannabis extract (2024)

3 citations DOI OpenAlex
Inter-strain variability in responses to a single administration of the cannabidiol-rich cannabis extract in mice (2024)

1 citation DOI OpenAlex
Investigating the relationship between hypoxia, hypoxia-inducible factor 1, and the optical redox ratio in response to radiation therapy (2024)

4 citations DOI OpenAlex
Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix (2024)

14 citations DOI OpenAlex
The Malignant Potential of Ovarian Steroid Cell Tumors Revisited (2024)

7 citations DOI OpenAlex
Endometriosis and Endometriosis-Associated Tumors (2024)

1 citation DOI OpenAlex
Gynecologic and Obstetric Pathology (2024)

14 citations DOI OpenAlex
BHLHE40 drives protective polyfunctional CD4 T cell differentiation in the female reproductive tract against Chlamydia (2024)

2 citations DOI OpenAlex
Coexpression of p53 and p16 in Vulvar Squamous Neoplasia (2023)

3 citations DOI OpenAlex
A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3). (2023)

2 citations DOI OpenAlex
Uterine alveolar soft part sarcoma – an unexpected case (2023)

1 citation DOI OpenAlex